NPS Pharmaceuticals receives orphan drug designation for Natpara in Europe NPS Pharmaceuticals announced that the European Commission has granted orphan drug designation to Natpara for the treatment of hypoparathyroidism. Orphan drug designation in the European Union is given to products that are designed for the diagnosis, prevention or treatment of rare diseases that are life-threatening or chronically debilitating. The company was also granted orphan drug status by the U.S. Food and Drug Administration in 2007. The company submitted its U.S. Biologic License Application to FDA in October 2013.
News For NPSP From The Last 14 Days
Check below for free stories on NPSP the last two weeks.